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Abstract In recent years great progress has been made in understanding the function of
ionotropic and metabotropic glutamate receptors; their pharmacology and potential ther-
apeutic applications. It should be stressed that there are already N-methyl-d-aspartate
(NMDA)antagonistsinclinicaluse,suchasmemantine,whichprovesthefeasibilityoftheir
therapeutic potential. It seems unlikely that competitive NMDA receptor antagonists and
high-afﬁnitychannelblockerswillﬁndtherapeuticuseduetolimitingside-effects,whereas
agents acting at the glycineB site, NMDA receptor subtype-selective agents and moderate-
afﬁnitychannelblockersarefarmorepromising.Thisissupportedbythefactthatthereare
severalglycineB antagonists,NMDAmoderate-afﬁnitychannelblockersandNR2B-selective
agentsunderdevelopment.PositiveandnegativemodulatorsofAMPAreceptorssuchasthe
AMPAkines and 2,3-benzodiazepines also show more promise than e.g. competitive antag-
onists. Great progress has also been made in the ﬁeld of metabotropic glutamate receptors
since thediscovery ofnovel,allosteric modulatorysites forthesereceptors. Selectiveagents
acting at these transmembrane sites have been developed that are more drug-like and have
amuchbetteraccesstothecentralnervoussystemthantheircompetitivecounterparts.The
chapter will critically review preclinical and scarce clinical experience in the development
ofnewionotropicandmetabotropicglutamatereceptormodulatorsaccordingtothefollow-
ing scheme: rational, preclinical ﬁndings in animal models and ﬁnally clinical experience,
where available.
Keywords G l u t a m a t er e c e p t o r s·I o n o t r o p i c·M e t a b o t r o p i c·A M P A·N M D A·K a i n a t e·
Stroke · Traumatic brain injury · Alzheimer’s disease · Parkinson’s disease ·
Huntington’s disease · Amyotrophic lateral sclerosis · Anxiety · Depression · Pain ·
Schizophrenia · Drug tolerance · Drug abuse
1
Introduction
Glutamateistheprincipalexcitatoryneurotransmitterinthemammaliancen-
tral nervous system(CNS) and is involved in virtually all functions of the CNS
(Mayer and Armstrong 2004). This provides the basis, on the one hand, for
therapeutic intervention in many brain dysfunctions, but on the other hand,
for potential side-effects. After release from presynaptic terminals, glutamate
binds to both ionotropic and metabotropic receptors to mediate fast, slow,
and persistent effects on synaptic transmission and integrity (McFeeters and
Oswald 2004). Many studies have expanded the functional repertoire of glu-
tamate by showing that glutamate receptors are also present in a variety of
non-excitable cells such as astrocytes (Nedergaard et al. 2002).
Synaptic strength at glutamatergic synapses shows a remarkable degree of
use-dependent plasticity and such modiﬁcations may represent a physiologi-
cal correlate to learning and memory. Two prominent examples are long-term
potentiation (LTP) and long-term depression (LTD), whose mechanisms have
been the subject of considerable scrutiny over the past few decades. Dynamic
regulationofsynapticefﬁcacyisthoughttoplayacrucialrolealsoinformation
ofneuronalconnectionsandexperience-dependentmodiﬁcationofneuralcir-Excitatory Amino Acid Neurotransmission 251
cuitry (Lamprecht and LeDoux 2004). The rodent whisker-to-barrel system is
used as a model of activity-dependent cortical plasticity. Specialized anatom-
ical conﬁgurations called ‘barrels’ are structurally and functionally linked to
individual whiskers. Much like the reorganization of the human cortex after
amputation, peripheral injury resulting from ablation of a single whisker fol-
licle produces atrophy of the cortical barrel connected to it, and enhanced
growth of surrounding barrels. The rearrangement of synaptic connections
during normal and deprived development is though to be controlled by corre-
lations in glutamatergic afferent impulse activity (Schierloh et al. 2004).
Themolecularandcellularmechanismsbywhichsynapticchangesaretrig-
geredandexpressedarethefocusofintenseinterest(SongandHuganir2002).
Manyoftheproteinsinvolvedinthephysiologyofglutamatergicsynapseshave
been cloned and their functional role is currently deﬁned. Rapid changes in
cytoskeletal and adhesion molecules after learning contribute to short-term
plasticity and memory, whereas later changes, which depend on de novo pro-
tein synthesis as well as the early modiﬁcations, seem to be required for the
persistence of long-term memory (Sheng and Kim 2002). The mechanisms of
this structural plasticity are still poorly understood, but recent ﬁndings are
beginning to provide clues (Xu-Friedman and Regehr 2004).
Various aspects of synaptic ultra structure have also been implicated in
the mechanisms of short-term plasticity (Dodt et al. 1999, 2002; Eder et al.
2003)andinformationgating(GovindaiahandCox2004)orrhythmicactivity
(Hughesetal.2004)mediatedbyionotropicandmetabotropicglutamaterecep-
tors (mGluRs). There is increasing evidence that dendritic spines undergo an
activity-dependent structural remodelling and memories are created by alter-
ations in glutamate-dependent excitatory synaptic transmission on dendritic
spines (Kasai et al. 2003). The changes in synaptic transmission are initiated
by elevations in intracellular calcium and consequent activation of second
messenger signalling pathways in the postsynaptic neuron. A large family of
interacting proteins regulates glutamate receptor turnover at synapses and
thereby inﬂuences synaptic strength (Carroll and Zukin 2002). Neuronal ac-
tivity controls this highly dynamic process of synaptic receptor targeting and
trafﬁcking. The targeting, trafﬁcking and internalization mechanisms of glu-
tamatereceptorsareorganizedatsynapsesbycytoskeletalproteinscontaining
multiple protein-interacting domains. The physical transport of glutamate re-
ceptors in and out of the synaptic membrane contributes to several forms of
long-lasting synaptic plasticity. These modiﬁcations are then actively stabi-
lized, over hours or days, by structural changes downstream from glutamate
receptors (McGee and Bredt 2003). Recent studies demonstrate that these
‘scaffolding’ proteins within the postsynaptic specialization do not only play
a role in the synaptic delivery and maintenance of the receptor assembly but
havealsothecapacitytopromotesynapticmaturation,inﬂuencesynapsesize,
and modulate glutamate receptor function. Given that glutamate receptors are
widely expressed throughout the CNS, regulation of their activity-dependent252 C.G. Parsons et al.
redistribution provides a potentially important way to modulate efﬁcacy of
synaptic transmission (Malinow and Malenka 2002; Bredt and Nicoll 2003).
Furthermore, recent results indicate that these distinct protein–protein inter-
actionsmaybesubtlyregulatedbyphosphorylation/dephosphorylationofthe
intracellular domains of receptor subunits (Flajolet et al. 2003).
Excitatory amino acid transporters (EAATs) are the primary regulators of
extracellular glutamate concentrations in the CNS. Glutamate clearance (and
consequentlyglutamateconcentrationanddiffusionintheextracellularspace)
i sa s s o c i a t e dw i t ht h ed e g r e eo fa s t r o c yt i cc o v e r a g eo fi t sn e u r o n s( O l i e te ta l .
2001). The genes encoding glutamate transporter proteins have been cloned
both from rats and humans (Arriza et al. 1994; Malandro and Kilberg 1996).
ThehumantransportersEAAT1andEAAT2(ratequivalentsGLASTandGLT1)
are found in astroglia and microglia and are widely distributed in the CNS.
Human EAAT3 (rat EAAC1) is restricted to neurons but is also found outside
of the CNS. Human EAAT4 is expressed by cerebellar neurons.
The vesicular glutamate transporter (VGLUT) is responsible for the active
transportofl-glutamateinsynapticvesiclesandthusisapotentialmarkerfor
the glutamatergic phenotype. VGLUT comprises three isoforms, VGLUT1, 2
and 3. Recent studies indicated that VGLUT is also expressed in non-neuronal
cells,andlocalizedwith variousorganelles suchas synaptic-likemicrovesicles
in the pineal gland, and hormone containing secretory granules in endocrine
cells. l-Glutamate is stored in these organelles, secreted upon various forms
of stimulation, and then acts as a paracrine-like modulator. Thus, VGLUTs
highlight a novel framework of glutamatergic signalling and reveal its diverse
modes of action (Amara and Fontana 2002).
Under various conditions neurons can become so sensitive to glutamate
that it actually kills them (‘excitotoxicity’; Rothman and Olney 1987) through
receptor-mediated depolarization and calcium inﬂux (Parsons et al. 1998). It
has been implied that excitotoxicity is involved in many types of acute and
chronic insults to the CNS (Choi 1995). Recent studies suggest that synaptic
N-methyl-d-aspartate (NMDA) receptors may also be involved in neuropro-
tective mechanisms (Lu et al. 2003). Disturbance of glutamate homeostasis
probably plays a pivotal role in the execution of pathological changes in many
disease states and may be triggered by a wide variety of factors that facili-
tate the neurotoxic potential of endogenous glutamate. These factors include:
increase in glutamate release, malfunctioning of neuronal and glial uptake,
energy deﬁcits, neuronal depolarization, changes in glutamate receptor prop-
erties or expression patterns, and free radical formation (Danysz et al. 1995;
Beal 1995; Parsons et al. 1998). Such excitotoxic effects can be pronounced
during acute events, such as ischaemic stroke and trauma, or milder but pro-
longed in chronic neurodegenerative diseases such as Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease and amyotrophtropic lateral scle-
rosis (ALS) (Starr 1995; Beal 1995; Plaitakis et al. 1996; Parsons and Danysz
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disorders such as schizophrenia, anxiety, and depression (Danysz et al. 1995;
Parsons et al. 1998), as well as in the development of disorders associated with
long-termplasticchangesintheCNSsuchaschronicpain,drugtolerance,de-
pendence, addiction, partial complex seizures and tardive dyskinesia (Danysz
etal.1995;TrujilloandAkil1995;Dickenson1997;Parsonsetal.1998).Bothen-
vironmental and genetic glutamate receptor manipulations enhance learning
andmemory(Tangetal.2000a,b).Geneticmanipulationconferringenhanced
cognitive abilities may also provide unintended traits, such as increased sus-
ceptibility to persistent pain (Tang et al. 2001).
2
GlutamateReceptors
Glutamate receptors are divided into ionotropic receptors (directly coupled to
anionchannel)andmetabotropicreceptors(coupledtointracellularsignalling
cascades).
2.1
IonotropicGlutamateReceptors
There are three types of ionotropic glutamate receptors: NMDA, α-amino-3-
hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA), and kainate receptors
(Fig. 1). Each is principally activated by the agonist bearing its name and
is permeable to cationic ﬂux; hence, their activation results in membrane
depolarization.Ionotropicglutamatereceptorswereoriginallyclassiﬁedbased
on three selective, synthetic agonists: quisqualate, kainate and NMDA. After
the discovery of metabotropic receptors, it became clear that quisqualate also
interactswiththem.Sincethattime,quisqualate-sensitiveionotropicreceptors
have been classiﬁed by the more selective agonist AMPA.
All ionotropic glutamate receptors can form heteromeric subunit assem-
blies that have different physiologicaland pharmacologicalproperties and are
differentiallydistributedthroughouttheCNS(McbainandMayer1994;Danysz
et al. 1995;Parsons et al. 1998;Danysz and Parsons 1998).Both AMPA (Rosen-
mundetal.1998)andNMDAreceptors(Laubeetal.1998)areprobablylargely
formed from tetrameric, heteromeric assemblies of different subunits (Man-
sour et al. 2001). The four distinct subunits are believed to be topologically
arranged with three transmembrane-spanning and one pore-lining (hairpin
loop) domain (Madden 2002).
High-resolution studies of ionotropic glutamate receptor (iGluR) extracel-
lulardomainsarebeginningtobridgethegapbetweenstructureandfunction.
Crystal structures have deﬁned the ligand-binding pocket well beyond what
was suggested by mutational analysis and homology models alone, providing
initial suggestions about the mechanisms of channel gating and desensiti-
zation. Nuclear magnetic resonance (NMR)-derived backbone dynamics and254 C.G. Parsons et al.
Fig.1 Ionotropic glutamate receptors: subtypes and sequence homology
molecular dynamics simulations have added further insights into the role of
p r o t e i nd yn a m i c si nr e c e p t o rf u n c t i o n .
2.1.1
AMPAReceptors
AMPA receptors are involved in mediating most forms of fast glutamater-
gic neurotransmission. There are four known subunits, GluR1 to GluR4—
sometimes termed GluRA to GluRD—which are widely, but differentially, dis-
tributedthroughouttheCNS(Fig.2;Parsonsetal.1998).Thetypesofsubunits
formingthesereceptorsdeterminetheirbiophysicalpropertiesandpharmaco-
logicalsensitivity.AMPAisselectiveforGluR1-toGluR4-containingreceptors
and induces strong desensitization. Two alternative splice variants of GluR1
to GluR4 subunits designated as ‘ﬂip’ and ‘ﬂop’ have been shown to differ in
their expression throughout the brain and during development and to impart
differentpharmacologicalproperties(Sommeretal.1990;Monyeretal.1991).
The GluR2 subunit imparts particular properties to heteromeric AMPA re-
ceptors. Receptors containing this subunit show low Ca2+ permeability, linear
current-voltage relationships and low sensitivity to block by polyamines and
spider toxins. Receptors lacking this subunit show relatively high Ca2+ perme-
ability (Burnashev 1996), strong rectiﬁcation, i.e. non-linear current-voltage
relationships(Verdoornetal.1991)mediatedbychannelblockadeviaintracel-Excitatory Amino Acid Neurotransmission 255
Fig.2 S c h e m a t i co fA M P Ar e c e p t o rp h a r m a c o l o gy ,s u b t yp e sa n dt o p o l o gy
lular polyamines such as spermine (Bowie and Mayer 1995), and are sensitive
toblockbytoxinssuchasJorospidertoxin,philanthotoxin-343andargiotoxin-
636(seeParsonsetal.1998).TheGluR2subunitshowsdevelopmentallydistinct
edited and unedited—posttranslationalmodiﬁedprotein—forms (Burnashev
1996), and it is the presence of a positively charged arginine (R) residue in the
second membrane-inserted segment (MIS, position 586) of edited receptors
that renders them Ca2+ impermeable. Unedited homomeric GluR2 receptors
a r ea l s om u c hm o r es e n s i t i v et ot h ep o s i t i v em o d u l a t o r ye f f e c t so fc y c l o t h -
iazide. Cyclothiazide is a selective positive modulator of AMPA receptors,
whereas concanavalin-A is much more effective on kainate-preferring recep-
tors. 2,3-Benzodiazepines, such as GYKI 52466, are non-competitive AMPA
receptor antagonists and are much less active at kainate receptors (Bleakman
et al. 1996). Although the 2,3-benzodiazepines and cyclothiazide show strong
allostericinteractions,itisnowclearthattheseeffectsaremediatedatdifferent
recognitionsites(Rammesetal.1996,1998).Ingeneral,AMPAreceptorﬂipiso-
formsshowsomewhatslowerdesensitizationkineticsandaremoresensitiveto
thepositivemodulatoryeffectsofcyclothiazide.Glutamatereceptorsform‘hot
spots’ontheapicaldendriteofneocorticalneuronsoftherat(Fricketal.2001).
AlongthisstructureAMPAandNMDAreceptorsaredifferentiallydistributed.
Ca2+-permeable receptors are most prominent at early stages of develop-
mentandshowamuchmorelimiteddistributionintheadultbrain(Pellegrini-
Giampietroetal.1992).TherearesomeindicationsthatCa2+-permeableAMPA
receptors are expressed at higher levels under certain pathological conditions
such as global ischaemia (Goldberg et al. 1996). However, they also play an
important physiological role on inhibitory γ-aminobutyric acid (GABA) in-256 C.G. Parsons et al.
terneurons, and selective blockade could lead to excitotoxicity via disinhibi-
tion (Racca et al. 1996). Moreover, Ca2+-permeable AMPA receptors seem to
have an important role for correct structuralandfunctional relations between
Bergman glia and glutamatergic synapses in the cerebellum, such as the re-
movalofsynapticallyreleasedglutamate(Iinoetal.2001).Selectiveantagonists
provedtobeusefulinthepreventionandtreatmentofavarietyofneurological
and non-neurological diseases (Gitto et al. 2004).
2.1.2
AMPAReceptor-PositiveModulators
Cyclothiazide is a positive modulator of AMPA receptors that potentiates
agonist-induced currents by reducing or essentially eliminating desensitiza-
tion (Service 1994; Fricker 1997; Yamada 1998). Such ﬁndings underlie the
hypothesis that prolongation of AMPA–EPSC decay by inhibition of AMPA
receptordesensitizationmightincreasetheabilityofsynapticallyreleasedglu-
tamate to depolarize target neurons sufﬁciently to remove the Mg2+ blockade
ofNMDAreceptorsandthusfacilitatetheinductionofLTPandlearning.More
recent data indicate that cyclothiazide also prolongs AMPA receptor deactiva-
tionkinetics,i.e.decreasescurrent decayafteragonistremoval(Rammesetal.
1996, 1998) and this mechanism has been suggested to be more important for
AMPA receptor-positive modulators (Yamada 1998; see Rammes et al. 1999).
2.1.3
KainateReceptors
Physiological studies have identiﬁed both post- and presynaptic roles for
ionotropic kainate receptors. Kainate receptors contribute to excitatory post-
synaptic currents in many regions of the CNS including hippocampus, cortex,
spinal cord and retina. In some cases, postsynaptic kainate receptors are co-
distributed with AMPA and NMDA receptors, but there are also synapses
where transmission is mediated exclusively by postsynaptic kainate recep-
tors: for example, in the retina at connections made by cones onto off bipolar
cells. Extrasynaptically located postsynaptic kainate receptors are most likely
activated by ‘spill-over’ glutamate (Eder et al. 2003). Modulation of transmit-
ter release by presynaptic kainate receptors can occur at both excitatory and
inhibitory synapses. The depolarization of nerve terminals by current ﬂow
through ionotropic kainate receptors appears sufﬁcient to account for most
examples of presynaptic regulation; however, a number of studies have pro-
vided evidence for metabotropic effects on transmitter release that can be
initiatedbyactivationofkainatereceptors.Thehyperexcitabilityevokedbylo-
cally applied kainate, which is quite effectively reduced by endocannabinoids,
is probably mediated preferentially via an activation of postsynaptic kainate
receptors (Marsicano et al. 2003).Excitatory Amino Acid Neurotransmission 257
Fig.3 Schematic of kainate receptor pharmacology, subtypes and topology
Recent analysis of knockout mice lacking one or more of the subunits that
contribute to kainate receptors, as well as studies with subunit-selective ago-
nists and antagonists, have revealed the important roles that kainate receptors
play in short- and long-term synaptic plasticity. The subunits GluR5, GluR6,
KA1 and KA2 form receptor assemblies previously designated as high-afﬁnity
kainate receptors (Fig. 3). Kainate receptors were previously believed to be
largely presynaptic; for example, they are expressed in the dorsal root gan-
glia, and activation of these kainate receptors has been shown to facilitate
transmitter release (Schmitz et al. 2001). LTP and short-term synaptic facil-
itation is reduced in knockout mice lacking the GluR6, but not the GluR5,
kainate receptor subunit, suggesting that kainate receptors act as presynap-
tic autoreceptors on mossy ﬁbre terminals to facilitate synaptic transmission
(Contractor et al. 2001). Postsynaptic kainate receptors are involved in neu-
rotransmission in some pathways (Wilding and Huettner 1997; Lerma et al.
1997). Kainate receptor activation shows rapid and profound desensitization
of GluR5-, GluR6-, GluR7-, KA1- and KA2-containing receptors. SYM 2081,
previously assumed to be a kainate receptor antagonist, is actually an agonist
(Jones et al. 1997) which produces profound and rapid kainate receptor de-
sensitization and thereby acts as a functional antagonist when continuously
present (Wilding and Huettner 1997).
2.1.4
NMDAReceptors
NMDA receptors are highly permeant for Ca2+,s h o ws l o w e rg a t i n gk i n e t -
ics than AMPA receptors and the channel is blocked in a voltage- and use-
dependent manner by physiological concentrations of Mg2+ ions (Mcbainand258 C.G. Parsons et al.
Mayer 1994). These properties make them ideally suited for their role as a co-
incidence detector underlying Hebbian processes in synaptic plasticity such
as learning, chronic pain, drug tolerance and dependence (Collingridge and
Singer1990;TrujilloandAkil1995;DanyszandParsons1995;Collingridgeand
Bliss 1995; Dickenson 1997). Novel techniques revealed a differential distribu-
tion of NMDA receptors along apical dendrites of neocortical neurons (Frick
et al. 2001) and suggest a very localized generation of glutamate-induced
synaptic plasticity (Dodt et al. 1999; Frick et al. 2004). Two major subunit
families designated NR1 and NR2, as well as a modulatory subunit designated
NR3, have been cloned. Most functional receptors in the mammalian CNS are
formed by combination of NR1 and NR2 subunits that express the glycine and
glutamate recognition sites, respectively (Hirai et al. 1996; Laube et al. 1997).
2.1.4.1
NR1Subunits
Alternative splicing generates eight isoforms for the NR1 subfamily (Fig. 4;
Zukin and Bennett 1995). The variants arise from splicing at three exons. One
encodes a 21-amino acid insert in the N-terminal domain (N1, exon 5), and
two encode adjacent sequences of 37 and 38 amino acids in the C-terminal
domain(C1,exon21andC2,exon22).NR1variantsaresometimesdenotedby
Fig.4 Schematic representation of the NMDA receptorExcitatory Amino Acid Neurotransmission 259
thepresenceorabsenceofthesethreealternativelysplicedexons(fromNtoC1
to C2). NR1111 has all three exons, NR1000 has none, and NR1100 has only the
N-terminalexon.ThevariantsfromNR1000toNR1111arealternativelydenoted
as NMDA receptor 1-4a, -2a, -3a, -1a, -4b, -2b, -3b and -1b respectively. The
mRNAfordoublesplicevariants intheC1/C2regions,suchasNR1011 (NR1a),
show an almost complementary pattern to those lacking both of these inserts,
suchasNR1100 (NR1b);theformeraremoreconcentratedinrostralstructures
such as cortex, caudate, and hippocampus, while the latter are principally
found in more caudal regions such as thalamus, colliculi, locus coeruleus and
cerebellum (Laurie et al. 1995). NMDA receptors cloned from murine CNS
haveadifferentterminologyfromthoseintherat:ζ1remainstheterminology
f o rt h em o u s ee q u i v a l e n to fN R 1 ,a n dε1t oε4 represent NR2A to 2D subunits
respectively.
2.1.4.2
NR2Subunits
TheNR2subfamilyconsistsoffourindividualsubunits,NR2AtoNR2D(Figs.4
and5).VariousheteromericNMDAreceptorchannelsformedbycombinations
of NR1 and NR2 subunits are known to differ in gating properties, Mg2+ sen-
sitivity and pharmacological proﬁle (Parsons et al. 1998). The heteromeric
assembly of NR1 and NR2C subunits, for instance, has a lower sensitivity to
Mg2+ but increased sensitivity to glycine (see Sect. 2.2) and a very restricted
distribution in the brain. In situ hybridization has revealed overlapping but
Fig.5 Schematic of the NMDA receptor channel binding domain for Mg2+260 C.G. Parsons et al.
different expression for NR2 mRNA, e.g. NR2A mRNA is distributed ubiqui-
tously like NR1 with highest densities occurring in hippocampal regions and
NR2B is expressed predominantly in forebrain but not in cerebellum where
NR2Cpredominates.ThespinalcordexpresseshighlevelsofNR2CandNR2D
and these may form heteroligomeric receptors with NR1 plus NR2A, which
would provide a basis for the development of drugs selectively aimed at spinal
cord disorders.
The overexpression of NR2B in the forebrains of transgenic mice leads to
enhanced activation of NMDA receptors, facilitating synaptic potentiation in
response to stimulation at 10–100 Hz (Tang et al. 1999). These mice exhibit
superiorabilityinlearningandmemoryinvariousbehaviouraltasks,showing
that NR2B is critical for plasticity and memory formation. Environmental
enrichment signiﬁcantly increases protein levels of GluR1, NR2B and NR2A
(Rampon et al. 2000).
2.1.4.3
NR3Subunits
NR3 (NRL or Chi-1) is expressed predominantly in the developing CNS and
does not seem to form functional homomeric glutamate-activated channels,
but co-expression of NR3 with NR1 plus NR2 subunits decreases response
magnitude (Sucher et al. 1995; Matsuda et al. 2002). However, NR3A or NR3B
doesco-assemblewithNR1aloneinXenopusoocytestoformexcitatoryglycine
receptors that are unaffected by glutamate or NMDA, Ca2+-impermeable and
resistant to blockade by Mg2+ but inhibited by the glycine co-agonist d-serine
(Chatterton et al. 2002).
2.2
GlycineasaCo-agonist
Glycine is a co-agonist at NMDA receptors at a strychnine-insensitive recog-
nition site (glycineB), and its presence at moderate nanomolar concentrations
is a prerequisite for channel activation by glutamate or NMDA (Danysz and
Parsons 1998) and the prevention of NMDA receptordesensitization. Recently
it has been suggested that d-serine may be more important than glycine as
an endogenous co-agonist at NMDA receptors in the telencephalon and de-
veloping cerebellum. There is still some debate as to whether the glycineB site
is saturated in vivo (Danysz and Parsons 1998), but it seems likely that the
degree of NMDA receptor activation varies depending on regional differences
in receptor subtype expression and local glycine or d-serine concentrations.
Moreover, glycine concentrations at synaptic NMDA receptors could be ﬁnely
modulated by local expression of speciﬁc glycine transporters such as GLYT1
(Danysz and Parsons 1998).Excitatory Amino Acid Neurotransmission 261
2.2.1
Polyamines
Thepolyaminesspermineandspermidinehavemultipleeffectsontheactivity
of NMDA receptors (Johnson 1996; Williams 1997). These include an increase
inthemagnitudeofNMDA-inducedwhole-cellcurrentsseeninthepresenceof
saturating concentrations of glycine, an increase in glycine afﬁnity, a decrease
in glutamate afﬁnity, and voltage-dependent inhibition at higher concentra-
tions. Endogenous polyamines could act as a bi-directional gain control of
NMDAreceptorsbydampeningtoxicchronicactivationbylowconcentrations
of glutamate—through changes in glutamate afﬁnity and voltage-dependent
blockade—but enhancing transient synaptic responses to millimolar concen-
trations of glutamate (Williams 1997; Zhang and Shi 2001).
2.2.2
CompetitiveNMDAReceptorAntagonists
Antagonistssuchasd-(−)-2-amino-5-phosphono-valericacid(D-APV),which
competitively block NMDA receptors, cause numerous side-effects such as
memory impairment, psychotomimetic effects, ataxia and motor dis-coordi-
nation,sincetheyalsoimpairnormalsynaptictransmission.Thechallengehas
therefore been to develop NMDA receptor antagonists that prevent the patho-
logical activation of NMDA receptors but allow their physiological activation.
2.2.3
UncompetitiveNMDAReceptorAntagonists
It has been suggested that uncompetitive NMDA receptor antagonists with
rapidunblockingkineticsbutsomewhatlesspronouncedvoltage-dependency
than Mg2+ should be able to antagonize the pathological effects of the sus-
tained, but relatively small increases in extracellular glutamate concentration
but, like Mg2+, leave the channel as a result of strong depolarization following
physiological activation by transient release of millimolar concentrations of
synaptic glutamate (Parsons et al. 1993a; Parsons et al. 1999; Jones et al. 2001).
Assuch,uncompetitiveNMDAreceptorantagonistswithmoderate,ratherthan
highafﬁnitymaybedesirable.Memantineanddextromethorphanareclinically
usedagentsthatbelongtothiscategory.Severalpromisingagentshaveunfortu-
natelybeenabandonedatlatestagesofdevelopment,possiblyduetothechoice
of the wrong, too ambitious, clinical indications such as stroke and trauma.
2.3
GlycineSiteAntagonists
Most full glycineB antagonists (i.e. those without intrinsic partial agonist ac-
tivity) show very poor penetration to the CNS, although some agents with262 C.G. Parsons et al.
improved, but by no means optimal, pharmacokinetic properties have now
been developed. GlycineB antagonists have been reported to lack many of
the side-effects classically associated with NMDA receptor blockade such as
no neurodegenerative changes in the cingulate/retrosplenial cortex even af-
ter high doses and no psychotomimetic-like or learning impairing effects at
anticonvulsive doses (see Danysz and Parsons 1998). The Merck compound L-
701,324hasevenbeenproposedtohaveatypicalantipsychoticeffects(Bristow
et al. 1996). The improved neuroprotective therapeutic proﬁle of glycineB full
antagonists could be due to their ability to reveal glycine-sensitive desensiti-
zation (Parsons et al. 1993b).
Kynurenic acid is an endogenous glycineB antagonist, but it seems unlikely
that concentrations are sufﬁcient to interact with NMDA receptors under nor-
mal conditions (Danysz and Parsons 1998; Stone 2001). However, concentra-
tions are raised under certain pathological conditions (Danysz and Parsons
1998; Stone 2001) and interactions with other receptors such as α7n e u r o n a l
nicotinic have been reported at lower concentrations (Hilmas et al. 2001).
Strategies aimed at increasing kynurenic acid concentrations by, for example,
giving its precursor 4-Cl-kynurenine, inhibiting brain efﬂux with probenecid
orinhibitingitsmetabolismhavebeenproposedtobeoftherapeuticpotential
(Danysz and Parsons 1998; Stone 2001).
d-cycloserineand(+R)-HA-966arepartialagonistsattheglycineB sitewith
differentlevelsofintrinsicactivity(Karcz-Kubichaetal.1997).Althoughthese
systemicallyactivepartialagonistsdonotinducereceptordesensitizationthey
have favourable therapeutic proﬁles in some in vivo models (Lanthorn 1994;
see Danysz and Parsons 1998). This may, in part, be due to their own intrinsic
activityasagonistsattheglycineB site,whichwouldservetopreserveacertain
levelofNMD Areceptorfunctionevenatveryhighconcentrations(Dan yszand
Parsons 1998).
d-cycloserine shows agonist-like features at low in vivo doses, while with
increasing dosing antagonisticeffectspredominate (Lanthorn1994).The con-
sistentbiphasiceffectsofd-cycloserineseeninvivomayberelatedtodifferent
afﬁnities and intrinsic activities at NMDA receptor subtypes. d-cycloserine is
apartialagonistforthemurineequivalentsofNR1/2AandNR1/2Bheteromers
butismoreeffectivethanglycineatNR1/2C(O’Connor etal.1996).Thiseffect
is accompanied by higher afﬁnity at NR1/2C receptors—NR1/2C>NR1/2D>>
NR1/2B>NR1/2A (O’Connor et al. 1996). As such, it is likely that the biphasic
e f f e c t ss e e ni nv i v oa r ed u et oa g o n i s t i ca c t i o n sa tN R 1 / 2 Cr e c e p t o r sa tl o w e r
doses and inhibition of NR1/2A and NR1/2B containing receptors at higher
doses.Thisreceptorsubtypeselectivityanddifferentialintrinsicactivitycould
well underlie its promising preclinical proﬁle in some animals models.
T h e r ei sav e r yl a r g eb o d yo fl i t e r a t u r ec o n ﬁ r m i n gt h a td-cycloserine en-
hances learning in a wide variety of models (see Danysz and Parsons 1998 for
reviewplusHarper2000;Lelongetal.2001).Takentogether,thesedataindicate
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are only seen at a very narrow range of doses and that even these effects are
lost upon repetitive or chronic administration.
Although1-amino-cyclopropane-carboxylicacid(ACPC)hasbeenreported
to be a partial agonist with very high intrinsic activity, it is probably really
a full agonist at the glycineB site and actually behaves as an antagonist in
someinvivomodels(neuroprotection,anticonvulsiveeffects)thatarelikelyto
be mediated via competitive antagonistic properties at higher concentrations
(Skolnick et al. 1989). The consistent observation that chronic treatment with
ACPCisneuroprotectivecouldbebecauseitdesensitizesoruncouplesNMDA
receptors(Skolnicketal.1992;PappandMoryl1996),oritmayberelatedtoan
increase in the relative levels of NR2C expression (Danysz and Parsons 1998).
N-Acetyl-aspartyl-glutamate(NAAG),whichisabundantinthemammalian
CNS, acts as a weak partial agonist at NMDA receptors with low intrinsic ac-
tivity and an agonist at mGluR3 receptors (Neale et al. 2000). Inhibition of
NAALADase(N-acetyl-a-linked-acidicdipeptidase,orglutamatecarboxypep-
tidase II, E.C. 3.4.17.21) has been proposed to be useful in numerous CNS
disorders associated with disturbances in glutamatergic transmission by de-
creasing the concentration of glutamate and increasing the concentration of
NAAG.
2.3.1
NR2B-SelectiveAntagonists
Ifenprodil and its analogue eliprodil block NMDA receptors in a spermine-
sensitive manner and were originally proposed to be polyamine antagonists.
It is now clear that both agents are selective for NR2B subunits (Legendre and
Westbrook 1991) and bind to a site that is distinct from the polyamine recog-
nitionsite,but interact allostericallywiththissiteandtheglycineB site.NR2B-
selective agents may also offer a promising approach to minimize side-effects,
as agents would not produce maximal inhibition of responses of neurons ex-
pressing heterogeneous receptors. Thus, cortical and hippocampal neurons
expressbothNR2AandNR2Breceptorsinapproximatelysimilarproportions,
but very little NR2C or NR2D. NR2B-selective agents therefore block NMDA
receptor-mediated responses of such neurons to a maximal level of around
30%–50% of control. Several studies have shown that ifenprodil and eliprodil
reduce seizures and are effective neuroprotectants against focal and global
ischaemia and trauma at doses that do not cause ataxia or impair learning
(Parsons et al. 1998). An unfortunate new side-effect has recently been re-
ported, i.e. that some of these agents may produce a prolongation of the Q-T
intervalinthecardiacactionpotentialduetoblockadeofhumanether-a-go-go-
related gene (hERG) potassium channels (Gill et al. 1999). Several substances
selective for NR2B NMDA receptor subtypes such as traxoprodil, Ro-25-6981
andEMD-95885havebeenclaimedtohaveagoodneuroprotectiveproﬁle,and
traxoprodilisinclinicaldevelopment.Otherpromisingagentshavebeenaban-264 C.G. Parsons et al.
doned at various stages of clinical development, but often due to side-effects
unrelated to NMDA receptor antagonism.
2.3.2
δ-GlutamateReceptors
Whilemostsubtypesofglutamatereceptorshavebeenstudiedextensively,less
isknown abouttheδ-glutamatereceptors,δ1andδ2,whichare abundant only
in parallel ﬁbre synapses on Purkinje cells. Although neither forms functional
channels when expressed in heterologous cells, genetic analyses have demon-
strated the physiological signiﬁcance of δ2. A δ-glutamate receptor-binding
protein was identiﬁed in the rat, which is widely expressed in both brain and
peripheral tissues, including high expression in brainstem and enrichment in
the postsynaptic density. Morphological changes in this binding protein may
regulate the δ-glutamate receptor clustering on the dendritic spines, and may
affect synaptic efﬁcacy and plasticity (Hirai 2000; Ly et al. 2002).
2.4
MetabotropicGlutamateReceptors
Eight genes encoding mGluRs have been identiﬁed. They are G protein (gua-
nine nucleotide-bindingprotein)-coupledreceptorslinkedtosecond-messen-
gersystems.Eachmetabotropicglutamatereceptoriscomposedofseventrans-
membrane-spanning domains, with only minor homology to GABA(B)-type
receptors, and appears evolutionarily distinct from the other members of the
superfamily of metabotropic G protein-coupled receptors (GCPRs), which in-
cludes noradrenergic, muscarinic, acetylcholinergic, dopaminergic and sero-
tonergic(exceptothertypeIIIGPCRssuchasGABABandCa2+ sensingrecep-
tors) receptors. mGluRs are divided into three major groups, I–III, which are
involved in the generation of slow excitatory and inhibitory synaptic poten-
tials,andmodulationofsynaptictransmission,aswellassynapticandneuronal
plasticity and development (Nakanishi et al. 1998). In addition to glutamate,
mGluRs are activated by ibotenate and quisqualate. They undergo constitutive
internalizationafteractivationbyglutamate.Thisglutamate-inducedinternal-
ization involves an arrestin- and clathrin-dependent pathway and is inhibited
byreceptor-inverseagonists(Pulaetal.2004).FunctionalmGluRsareprobably
dimerslinkedviaextracellulardisulphidebridges.TheextremeintracellularC-
terminus of theα-subunit of the G protein is important for the Gi/Go-coupled
group II and III mGluRs, and the second loop is probably coupled to phospho-
lipase C (PLC). The ﬁrst and the third loops are highly conserved (Pin et al.
1998).MGluRsinteractwithHomerproteinsviaaproline-richmotifwithinthe
intracellular C-terminus. The Homer 1a isoform, which is upregulated during
seizures, stimulates group I mGluRs in the absence of an agonist (Ango et al.
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cellular signal regulated kinase (ERK)1/2 can activate some immediate early
genes (IEGs) encoding transcription factors (Peavy and Conn 1998; Ferraguti
et al. 1999).
Group I of mGluRs consists of two receptor subtypes, mGluR1, which has
four splice variants, and mGluR5, which has two splice variants. The group I
mGluRs are mainly localized to the somatodendritic membrane, and their
postsynaptic activation most commonly evokes excitation in neurons. Activa-
tion of presynaptic group I mGluRs reduces glutamate release and increases
paired-pulse facilitation, e.g. in hippocampal neurons (Manzoni and Bockaert
1995). Postsynaptic group I of mGluRs are positively coupled to PLC. PLC
promotes the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2)t o
diacylglycerol(DAG) andIP3.DAGactivates membrane-boundproteinkinase
(PK)C that in turn can phosphorylate ionotropic glutamate receptors. IP3 has
numerous intracellular effects including stimulation of Ca2+ release from in-
tracellular stores. Purkinje cells in the cerebellum carry exclusively mGluR1
including the two splice variants targeted to the perisynaptic regions (Mateos
et al. 2000) but no mGluR5. In the cerebellum, AMPA receptors mediate the
fast synaptic responses to glutamate released from parallel ﬁbres. Only tetanic
parallel ﬁbre stimulation evokes a slow mGluR1-mediated excitation. There is
evidencethatthisslowtimecourseisnotduetoaslowdiffusionofsynaptically
releasedglutamatebuttoanindirectsignaltransductionmechanismdifferent
from that active in hippocampal pyramidal neurons (Reichelt and Knöpfel
2002). The depolarizing current following mGluR1 activation in Purkinje cells
might be carried largely by Na+-ions (Tempia et al. 2001). In ventral midbrain
dopamineneurons,theactivationofmGluR1triggersaslowinhibitorysynap-
tic potential.Thissynaptic event iscausedbyapotassiumconductancethat is
activatedbyanincreaseinintracellularCa2+concentrationduetomobilization
from intracellular stores (Fiorillo and Williams 1998). The ﬁrst neurophysio-
logical recordings revealed that group I mGluR activation blocks a potassium
c o n d u ct a n c ei nt h eh i p p oc a m p u si nvi tr ot h a tw a stri gg e r e db yt h ei n c r e a s ei n
intracellularCa2+ followingtheopeningofvoltage-gatedCa2+ channelsduring
action potential generation. In the presence of the antagonist, action potential
was generated throughout the depolarizing input. Voltage-clamp experiments
demonstrated that the calcium-activated potassium current (IAHP) decreased
while the Ca2+ dynamics remained unchanged (Charpak et al. 1990). The
t w od i f f e r e n ts p l i c ev a r i a n t so ft h em G l u R 1s e e mt ob ei n v o l v e di nd i f f e r e n t
signalling pathways (Mannaioni et al. 2001).
Metabotropic glutamate receptor (mGluR) antagonists co-applied with do-
pamine block LTD in rat prefrontal cortex (PFC). This suggests that the
dopamine-facilitated LTD requires synaptic activation of groups I and II
mGluRs during tetanus (Otani et al. 1999).Activation of mGluRs causes mem-
brane hyperpolarization in midbrain dopamine neurons. This hyperpolariza-
tionresultsfromtheopeningofCa2+-sensitiveK+ channels,whichismediated
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polarization was shown to induce a transient pause in the spontaneous ﬁring
of dopamine neurons. The mGluR-mediated Ca2+ mobilization in dopamine
neuronsiscausedbymultipleintracellularpathwaystoexertaninhibitorycon-
trolontheexcitabilityofdopamineneurons(Morikawaetal.2003).Dopamine
neurons of the substantia nigra pars compacta receive a prominent serotonin
(5-HT) projection from the dorsal raphé nucleus. MgluR-evoked postsynaptic
currentsareinhibitedbyanactivationof5-HT2Aand5-HT4receptors(Paolucci
et al. 2003).
Group II (mGluR2/3) and group III (mGluR4/6/7/8; mGluR4/7/8 have two
splice variants) receptors differ in their sequence homology but are both cou-
pled to a different effector system, i.e. they decrease the activity of adenylate
cyclase. Both group II and III mGluRs are located largely on presynaptic
neurons and glia and modulate the release of glutamate as well as other,
e.g. inhibitory, transmitters such as GABA (Salt et al. 1999). The activation
of group II and III mGluRs evokes predominantly inhibitory effects on neu-
ronalexcitability.However,4-aminopyrrolidine-2,4-dicarboxylicacid(APDC),
a selective and potent group II mGluR agonist, reversibly increased NMDA
receptor currents in acutely dissociated PFC pyramidal neurons. Selective
group II mGluR antagonists, but not group I mGluR antagonists, blocked
APDC-induced enhancement of NMDA receptor currents, suggesting the me-
diation by mGluR2/3 receptors. Inhibiting PKC or dialysis with Ca2+ chela-
tors largely blocked the mGluR2/3 modulation of NMDA receptor currents.
Moreover, treatment of PFC slices with APDC signiﬁcantly increased the PKC
activity and PKC phosphorylation of NMDA receptors. These ﬁndings suggest
that activation of mGluR2/3 receptors potentiates NMDA receptor channel
functions in PFC through a PKC-dependent mechanism (Tyszkiewicz et al.
2004).
A very interesting ﬁnding is that AMPA receptor activation inhibits ADP-
ribosylation and forskolin-stimulated activity of adenylate cyclase in rat cor-
tical neurons (Wang et al. 1997). These effects were independent of Ca2+ and
Na+ inﬂux, suggesting that the ionotropic AMPA receptor is also directly cou-
pled to metabotropic processes. This is supported by the ﬁnding that AMPA
receptorsactivateaGprotein(KawaiandSterling1999).Briefkainateexposure
caused long-lasting inhibition of a post-spike potassium current (I sAHP) in
CA1 pyramidal cells and this inhibition did not require ionotropic action or
network activity, but was blocked by an inhibitor of pertussis toxin-sensitive
G proteins (ethylmaleimide), or the PKC inhibitor calphostin C (Melyan et al.
2002). Agonist-dependent downregulation of recombinant NR1/2A receptors
by tyrosine dephosphorylation independent of ion ﬂux has also recently been
reported (Vissel et al. 2001).
Recent data suggestthat a progressive increase in tonic mGluR activity dur-
ing postnatal development contributes to a reduction of release probability
of glutamate in excitatory cortical synapses (Chen and Roper 2004). Group I
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Table1 Metabotropic glutamate receptors
Group I Group II Group III mGIuRs connected
with PLD
Subtypes mGIuR1 MgIuR2 mGIuR4 Non-identiﬁed
mGIuR1a MgIuR3 mGIuR4a
mGIuR1b mGIuR4b
mGIuR1c mGIuR6
mGIuR1d mGIuR7
mGIuR5 mGIuR7a
mGIuR5a mGIuR7b
mGIuR5b mGIuR8
Second messenger system ↑ PLC ↓ AC ↓ AC ↑ PLD
↑,Increase;↓,decrease;AC,adenylatecyclase;PLC,phospholipaseC;PLD,phospholipaseD.
identiﬁed septohippocampal cholinergic neurons (Hajszan et al. 2004). Septo-
hippocampal cholinergic neurons innervate the hippocampus and provide it
with almost its entire acetylcholine. These ﬁndings may be of signiﬁcance in
treatmentofcognitivedeﬁcitsassociatedwithneurodegenerativedisorders,as
mGluR-mediated activation of septohippocampal cholinergic neurons would
enhance the release of acetylcholine both in the hippocampus and in the sep-
tum. NMDA receptor-independent LTP has been shown to be mediated by
activation of group II mGluRs (Wu et al. 2004).
The prominent involvement of mGluRs in genomic responses to synaptic
stimulation is considered to play a pivotal role in a variety of neurological
disorders. Available data indicate that the eight subtypes of mGluRs have
distinct effects on gene expression. The group I subtypes facilitate, whereas
group II and III subtypes inhibit, gene expression. Due to their signiﬁcance
in regulating drug action, mGluRs have been considered as promising targets
for the development of novel therapeutic drugs for the treatment of drug
addiction. It seems likely that allosteric modulation of mGluRs may provide
avalidstrategyforthedevelopmentofnewpharmaceuticalsinthenearfuture
(Gasparinietal.2002).Numeroushighlyselectiveagonistsandantagonistsare
now available (Knöpfel et al. 1995; Schoepp et al. 1999; Table 1).
3
SynapticPlasticity
NMDA receptor channels are only activated in the presence of a local strong
depolarization induced by strong AMPA receptor activation and concurrent268 C.G. Parsons et al.
GABAergic disinhibition via feedback effects of GABA on GABAB autorecep-
t o r s .A sar e s u l t ,t h eM g 2+ b l o c k a d eo fN M D Ar e c e p t o r si st r a n s i e n t l yf u l l y
relieved allowing Ca2+ to ﬂow into the postsynaptic neuron. This Ca2+ inﬂux
triggers a cascade of secondary messengers that ultimately activate a number
ofenzymessuchasPK C,phospholipaseA 2 (PLA2),PLCandCa2+/calmodulin-
dependent protein kinase II (CaM kinase II) (Abraham and Tate 1997; Grant
and Silva 1994; Lisman 1994; Benowitz and Routtenberg 1997; Lan et al. 2001;
Bayer et al. 2001). Consequently, these processes lead to ﬁxation of changes in
postsynapticAMPAreceptorssuchasanincreaseintheirafﬁnityand/ornum-
ber (Benke et al. 1998) and, possibly through retrograde signals (arachidonic
acid, nitric oxide), modulate presynaptic glutamatergic terminals inﬂuencing
transmitter release (Collingridge and Bliss 1995).
T h e r ei sa c c u m u l a t i n ge v i d e n c et h a tL T Pa n dL T Ds h a r es o m ec o m m o n
mechanisms, although LTD occurs with increases in postsynaptic Ca2+ that
are insufﬁcient to induce LTP (Artola and Singer 1993; Christie et al. 1994;
Cummings et al. 1996; Derrick and Martinez 1996; Hansel et al. 1996; Kirk-
wood et al. 1996; Tsumoto and Yasuda 1996). Although hippocampal LTP and
spatial learning are impaired by NMDA receptor blockade, learning deﬁcits
can be almost completely prevented if rats are pretrained in a different water
maze (Bannerman et al. 1995; Saucier and Cain 1995). NMDA receptors may
therefore not be required for encoding the spatial representation of a speciﬁc
environment,butratherotherformsofmemorythatareimportantforlearning
the water maze task (Morris 1996). Recent evidence indicates that LTP is not
only important for synaptic plasticity in the mature CNS but also in the for-
mation of conducting glutamatergic synapses in the developing mammalian
brain (Durand et al. 1996).
Thereisstillconsiderabledebateastothesiteatwhichtheincreaseinsynap-
tic strength is expressed (Collingridge and Bliss 1995). Presynaptic mech-
anisms should be reﬂected in a change in release probability. This can be
measured at excitatory synapses on cultured hippocampal neurons by anal-
ysis of the progressive block of NMDA receptor-mediated synaptic currents
by the essentially irreversible open channel blocker dizocilpine [(+)MK-801]
(Rosenmund et al. 1998). This technique was used to demonstrate that release
probability was not affected after the induction of LTP, making a presynaptic
mechanism unlikely (Manabe and Nicoll 1994). Moreover, recent reports in-
dicate that a high proportion of synapses in hippocampal area CA1 transmit
with NMDA receptors but not AMPA receptors, making these synapses effec-
tively non-functional at normal resting potentials due to Mg2+ blockade (Liao
etal.1995;NicollandMalenka1995;Montgomeryetal.2001;Montgomeryand
Madison2002).ThesesilentsynapsesacquireAMPA-typeresponsesfollowing
LTPinduction.Furthermore,thisformofLTPisaccompaniedbyanincreasein
the conductance of postsynaptic AMPA receptors. Taken together, these ﬁnd-
ings challenge the view that LTP in CA1 involves a presynaptic modiﬁcation,Excitatory Amino Acid Neurotransmission 269
and suggest instead a simple postsynaptic mechanism for both induction and
expression of LTP.
Cerebellar LTP was reduced in mGluR1 knockout mice (Aiba et al. 1994)
whereas mGluR5 knockout mice exhibited a normal LTD (Lu et al. 1997). The
targetedreplacementofGluR1ainonlyPurkinjecellsre-establishedLTDagain
(Ichise et al. 2000).
4
Pathophysiology
Endogenous glutamate, by activating ionotropic and metabotropic glutamate
receptors, may contribute to the brain damage occurring acutely after status
epilepticus, cerebral ischaemia or traumatic brain injury and may also con-
tributetochronicneurodegenerationinsuchdisordersasAlzheimer’sdisease,
Parkinson’s disease, ALS and Huntington’s chorea. There is no evidence at
presentthatdietaryglutamate—glutamateisthemostabundantaminoacidin
the diet—can evoke brain damage in humans. However, the kainate analogue,
domoate,whichissometimesingestedaccidentallyinbluemussels,isapotent
neurotoxin. This neurotoxin evokes seizures and can lead to hippocampaland
related pathology and amnesia.
4.1
Stroke
There are a number of microdialysis studies in animals indicating that there
is a consistent increase in extracellular glutamate concentration during exper-
imental ischaemia (Benveniste et al. 1984; Globus et al. 1988). In man, there is
alsoanincreaseinCSFandplasmacontentofglutamateandglycineinpatients
with progressive, but not with stable stroke (Castillo et al. 1997).
Considering the shortage of energy in neurons during ischaemia, an in-
creaseinextracellularglutamateconcentrationperseisnotnecessarytoevoke
damage through activation of glutamate receptors. Other factors may increase
neuronal vulnerability to physiological levels of glutamate simply by, for ex-
ample, a decrease of resting membrane potential or buffering of intracellu-
lar Ca2+. Apart from glutamate, oxidative stress, inﬂammatory reactions and
break-down of the blood–brain barrier may also play a role (Ginsberg 1995).
In general, AMPA receptor antagonists seem to be more active in global
ischaemia models, while both NMDA and AMPA receptor antagonists show
moderate activity in focal ischaemia (for review see Parsons et al. 1998 plus
Schielkeetal.1999;KawasakiYatsugietal.2000;Lees2000;Pitsikasetal.2001).
Several clinical trials with glutamate antagonists have consistently failed to
show beneﬁcial effects in stroke (Lodder 2000). In these studies some CNS
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werereportedforcompetitiveandhigh-afﬁnityuncompetitiveNMDAreceptor
antagonists (Davis et al. 2000).
Activation of group I mGluRs has been implicated in the pathophysiology
of acute CNS injury (Bao et al. 2001). However, only rather high concentra-
tions of the selective mGluR5 antagonists 2-methyl-6-phenylethynylpyridine
(MPEP) and (R,S)-2-chloro-5-hydroxyphenylglycine (CHPG) reduce infarct
v o l u m ea n dl e a dt oas i g n i ﬁ c a n tn e u r o l o g i c a lr e c o v e r y .
4.2
CNSTrauma
Following traumatic brain injury (TBI) in rats there are clearly perturbations
of energy homeostasis and a signiﬁcant increase of extracellular glutamate
(Zauner and Bullock 1995). An increase in glutamate content has also been
observed in patients using brain microdialysis (Kanthan and Shuaib 1995) or
CSF sampling (Palmer et al. 1994). Interestingly, a delayed rise in extracellular
levelsofglutamatethatpersistedforseveraldaysaftertraumaticinsulthasbeen
observed in some patients, and was often connected with a poor prognosis
(Bullock et al. 1995).
Pre-treatment with either NMDA or AMPA receptor antagonists provides
neuroprotection in animal models of TBI. For example, recent data indicate
that treatment of rats with memantine immediately after injury signiﬁcantly
preventedneuronallossinbothCA2andCA3regionsafterTBIinducedinadult
rats with a controlled cortical impact device (Rao et al. 2001). NR2B-selective
antagonistssuchastheﬁrstgenerationagentifenprodilandthemoreselective
agenttraxoprodilwerealsoprotectiveinanimalmodelsofTBI(Okiyamaetal.
1997;Dempseyetal.2000)andsubduralhaematoma(Tsuchidaetal.1997).The
glutamate release inhibitor riluzole attenuated ﬂuid percussion cortical injury
when applied shortly after the insult (Wahl et al. 1997). Similarly, sipatrigine
signiﬁcantly reduced ﬂuid percussion injury-induced focal brain oedema in
the rat (Okiyama et al. 1995).
Laboratory studies have identiﬁed numerous glutamatergic targets for po-
tentialtherapeuticinterventionsinTBI(Bullocketal.1999).Ofthesepotential
therapies,onlyNMDAreceptorantagonists haveprogressedintohumanclini-
caltrials,but,asstatedabove,mostofthesetrialswereterminatedprematurely.
Activation of group I mGluRs attenuates excitotoxicity in oligodendrocytes
by controlling downstream oxidative stress after iGluR overactivation and
also prevents non-excitotoxic forms of oxidative stress by inhibiting reac-
tive oxygen species accumulation and intracellular glutathione loss. Group III
mGIuR4s (-6, -7, and -8) modulate neurotoxicity of excitatory amino acids
and epileptic convulsions, most likely via presynaptic inhibition of gluta-
matergic neurotransmission. Recent data provide evidence that also mGluR4
mediates neuroprotective effects (Maj et al. 2003). These ﬁndings suggest that
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that involve excitotoxic injury and/or oxidative stress to glial (Deng et al.
2004).
4.3
ChronicNeurodegenerativeDiseases
There are indications that there is an increase in either glutamate (decrease of
uptake and/or increase of release) or other endogenous glutamate receptors
agonistsinthevicinityofneuronsinAlzheimer’sdisease(seePalmerandGer-
shon1990andParsonsetal.1999forreviews).Asexamples,invitroβ-amyloid
enhances depolarization-stimulated glutamate release and inhibits its glial
uptake, and this effect is more pronounced in aged animals. β-Amyloid pep-
tide either activates NMDA receptors or enhances their sensitivity. In vivo
injection of β-amyloid i.c.v. produces long-lasting depression of EPSPs in
the hippocampus—an expression of ongoing mild excitotoxicity—that is pre-
ventedbythecompetitiveNMDAreceptorantagonist3-(2-carboxypiperazine-
4-yl)-propyl-1-phosphonic acid (CPP). Somewhat compatible is the ﬁnding
that β-amyloid (1–40) stimulates NO production by microglia. NO is known
to enhance glutamate release and to inhibit uptake (Lees 1993).
Sofar,themoderateafﬁnity,uncompetitiveNMDAreceptorantagonistme-
mantine is the only substance proﬁled for neurodegenerative dementia that
is already in clinical use. Memantine was recently registered for moderate to
severe Alzheimer’s disease in Europe [axura (Merz) and ebixa (Lundbeck)]
and in the USA [namenda (Forest)]. Preclinical data clearly indicate that me-
mantine might be able to slow down the progression of chronic neurodegen-
erative diseases (Danysz et al. 2000; Doraiswamy 2002; Möbius and Stöfﬂer
2002; Brown et al. 2003a; Areosa and Sherriff 2003). There are several reports
that memantine protects against acute NMDA or glutamate toxicity (Parsons
et al. 1999).
Although the production of new neurons declines during adulthood, it
has recently become clear that it indeed persists, although at very low levels,
in the aged hippocampus. This neurogenesis in the mature dentate gyrus
is suppressed by corticosteroids, and over activity of glutamatergic systems
may have a similar effect (Cameron et al. 1995; Mcewen 1996; Cameron et al.
1998). Thus, acute treatment with the NMDA receptor antagonists seems to
increase the number of proliferating cells, new neurons and radial glia-like
cells in the granule cell layer of the hippocampus of aged rats (Cameron et al.
1995;Gouldetal.1997;Nacheretal.2003)andpreventscorticosterone-induced
decreaseinproliferatingcells(Cameronetal.1998).Ontheotherhand,thereis
a net increase in neurogenesis in animals housed in an enriched environment
coupled with an improved performance in a spatial learning test (Nilsson
et al. 1999). Thus, it seems possible that while pathological activation of the
glutamatergic system may have detrimental effects on neurogenesis in the
matureCNS,physiologicalglutamatergicactivitywillhaveapositiveeffect.As272 C.G. Parsons et al.
such,blockadeofpathologicalandrestorationofphysiologicalNMDAreceptor
activation could facilitate neurogenesis in the CNS.
The advent of potent and centrally available subtype-selective ligands has
led to an extensive investigation of the role of mGlu receptor subtypes in neu-
rodegeneration. Pharmacological blockade of mGluR1 or mGluR5, or phar-
macological activation of mGluR2/3 or mGluR4/7/8 produces neuroprotec-
tion in a variety of in vitro or in vivo models (Bruno et al. 2001). mGluR5
antagonists may limit neuronal damage induced by a hyperactivity of N-
methyl-d-aspartate (NMDA) receptors, because mGluR5 and NMDA recep-
tors are physically and functionally connected in neuronal membranes. A se-
ries of observations suggest a potential application of mGluR5 antagonists in
chronic neurodegenerative disorders, such as ALS and Alzheimer’s disease.
MGluR2/3 agonists inhibit glutamate release, but also promote the synthesis
and release of neurotropic factors in astrocytes. These drugs may therefore
have a broad application as neuroprotective agents in a variety of CNS dis-
orders. Finally, mGluR4/7/8 agonists potently inhibit glutamate release and
have a potential application in seizure disorders. The advantage of all these
drugs with respect to NMDA or AMPA receptor agonists derives from the
evidence that mGlu receptors do not ‘mediate,’ but rather ‘modulate’ excita-
tory synaptic transmission. Therefore, it can be expected that mGluR ligands
produce less undesirable effects resulting from the inhibition of excitatory
synaptic transmission, such as sedation or an impairment of learning and
memory.
4.4
AmyotrophicLateralSclerosis
A L Si sad e v a s t a t i n gn e u r o l o g i c a ld i s o r d e rc h a r a c t e r i z e db ys e l e c t i v eu p p e r
and lower somatic, but not autonomic, motor neuron degeneration leading to
paralysis and eventually death. Other functions such as intellectual abilities
and sensory perception are preserved. Several theories regarding the patho-
genesis of ALS have emerged including glutamate excitotoxicity, free radical
oxidative stress, neuroﬁlament accumulation and autoimmunity (see Parsons
and Danysz 2002 for review).
TheroleoftheglutamatergicsysteminpathologyofALSiswelldocumented
but partially contradictory. The questions stem both from postmortem, brain
imaging and plasma/CSF studies in ALS patients and observations in animal
models (LaBella et al. 1997). The most widely accepted deﬁcit in sporadic
ALS patients seems to be a loss of glial glutamate uptake (EAAT2) protein
but not mRNA in the spinal cord (Rothstein et al. 1992, 1995; Fray et al. 1998;
Sasaki et al. 2000). Whatever the mechanism, changes in EAAT2 expression
probably result in an increase in synaptic glutamate concentrations leading to
excitotoxicity. This is clearly illustrated by the fact that an administration of
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hindlimb paresis (Rothstein et al. 1996). In fact, after glutamate loading there
isasigniﬁcantlyhigherincrease inglutamateandaspartate levelsinplasmain
ALS patients than in matched controls (Gredal and Moller 1995).
Over a decade ago, it was shown that the pattern of neuronal loss in the
spinal cord in patients suffering from ALS resembles that obtained after ex-
citotoxic lesions induced by kainate in animals (Hugon et al. 1989). Injection
of kainate to the spinal cord produces damage to motoneurons, while NMDA
lesions affect mainly dorsal horn neurons (Ikonomidou et al. 1996). Similarly,
short exposure to kainate in vitro results in selective Ca2+-dependent death of
motoneurons expressing Ca2+-permeant AMPA receptors, while dorsal horn
neurons are unaffected (Van Den Bosch et al. 2000).α-Motoneurons in organ-
otypic cultures of rat spinal cord are considerably more sensitive to kainate
and quisqualate than to NMDA toxicity (Saroff et al. 2000). This selective
motoneuron death is completely inhibited by the AMPA receptor antagonists
LY300164 and Joro spider toxin (selective for Ca2+ permeant receptors) (Van
Den Bosch et al. 2000). This suggests non-NMDA (AMPA or kainate) receptor
involvement.
One of the crucial questions is why certain motoneuron populations are
particularlypronetodeathinALS.Althoughthereisnoclear-cutanswer,oneof
thepossibilitiesisweakCa2+ bufferingcapacityconnectedwithloweredlevels
of cytoplasmic proteins responsible for such buffering, such as parvalbumin
and calbindin (Krieger et al. 1994; Roy et al. 1998).
The competitive AMPA receptor antagonist RPR 119990 was found to be
active in a transgenic mouse model of familial ALS (SOD1-G93A) where it
was able to improve grip muscle strength and glutamate uptake from spinal
synaptosomal preparations, and prolong survival (Canton et al. 2001). Most
of the evidence presented above points to a primary involvement of AMPA
receptors in neurodegeneration in ALS. In fact, data on NMDA receptors role
are scarce and clinical evidence rather discouraging.
Riluzole—the only drug registered as a disease-modifying agent for ALS—
delayed the development of motor impairment and prolonged life span in
superoxidedismutase(SOD)transgenicmice(Gurneyetal.1998)(Kenneletal.
2000).Inspiteofextensivestudies,theprecisemechanismofactionofriluzole
(RP 54274) remains elusive. Riluzole clearly decreases the synaptic release of
glutamate and other neurotransmitters (Bryson et al. 1996) and this effect is
probably secondary to inhibition of voltage-activated Na+ channels (VASCs)
(Doble 1996) and voltage-activated Ca2+ channels (VASCs, P/Q>N>>>L-type
channels) (Stefani et al. 1997; Huang et al. 1997; Yokoo et al. 1998).
T h ee v i d e n c eg i v e na b o v ei sp r o b a b l ys u f ﬁ c i e n tt oc o n s i d e rg l u t a m a t ea n -
tagonists as plausible neuroprotective treatment of ALS. Unfortunately, most
clinical trials with glutamate antagonists completed to date have not been en-
couraging. Dextromethorphan (NMDA channel blocker) showed no beneﬁt
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4.5
Parkinson’sDisease
T h e r ei ss o m ee v i d e n c et h a tn e u r o d e g e n e r a t i o no fd o p a m i n e r g i cp a t h w a y s
of the substantia nigra pars compacta (SNc) in Parkinson’s disease involves
excitotoxicity (Schmidt et al. 1990; Greenamyre and O’Brien 1991; Blandini
and Greenamyre 1998). In rats, NMDA receptor antagonists protect against
damageofdopaminergicneuronsinducedbythedopaminomimeticmetham-
phetamine (Sonsalla et al. 1991). In vitro, MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) application inhibits the astroglial glutamate transporter
(Hazelletal.1997),probablythroughfreeradicals.MPTPinducestoxicityand
Parkinsonian symptoms in rats and monkeys, and this is prevented either by
NMDAreceptorantagonistsorbylesionofthedescendingcortico-striatalglu-
tamatergic pathway (see Blandini and Greenamyre 1998; Parsons et al. 1998).
It is now widely accepted that NMDA receptor antagonists might mani-
fest their symptomatic anti-Parkinsonian effects by attenuating an imbalance
between dopaminergic and glutamatergic pathways within the basal ganglia
network (Schmidt and Kretschmer 1997; Danysz et al. 1997). Based on pre-
clinicaldata,onecouldspeculatethatNMDAreceptorantagonists(andmaybe
AMPA receptor antagonists) should provide some degree of neuroprotection
in Parkinson’s patients (Danysz et al. 1997).
Amantadine has a long history in the symptomatic treatment of Parkin-
son’sdisease.Severalrecentdouble-blind,placebo-controlledstudieshavecon-
ﬁrmed the impressive acute antidyskinetic effects of amantadine (Rajput et al.
1998; Verhagen Metman et al. 1998; Luginger et al. 2000; Del Dotto et al. 2001;
Shoghi-Jadidetal.2002).Onestudyalsoindicatesthatamantadine’s antidysk-
ineticbeneﬁtismaintainedforatleast1year(Metmanetal.1999).Therelated
compoundmemantinewasfound,asintheMPTPmonkey,tohavenoeffecton
dyskinesiainadouble-blindstudy;butitdidimproveparkinsoniansymptoms
(Merello et al. 1999). This indicates that the antidyskinetic effects of amanta-
dine may be unrelated to NMDA receptor antagonism (Danysz et al. 1997).
4.6
Huntington’sDisease
Evidence suggests that overactivation of NMDA receptors contributes to se-
lective degeneration of medium-sized spiny striatal neurons in Huntington’s
disease. The pattern of neuronal loss in the striatum in Huntington’s disease
is similar to that obtained after excitotoxic lesions in animals (Schwarcz and
Köhler 1983). Striatal neurodegeneration produced by mitochondrial toxins
3-NP and malonate (inhibitors of complex II–III), producing a similar type of
damage,alsoisattenuatedbylesionsoftheglutamatergicinputs,theglutamate
release inhibitor lamotrigine and/or NMDA receptor antagonists such as di-
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et al. 2000). Hence, it is likely that mitochondrial dysfunction evoked by these
toxins triggers a chain of reactions including excitotoxicity. In fact, there are
dataindicatingadeﬁcitofmitochondrialcomplexII–IIIactivityinthebrainsof
Huntington’spatients(Browneetal.1997).HEK293cellsco-expressingmutant
huntingtinwithpolyglutamineexpansion(htt-138Q)andeitherNR1A/NR2A-
or NR1A/NR2B showed a signiﬁcant increase in apoptotic cell death in the
presence of NMDA, and this difference was larger for NR1A/NR2B (Zeron
et al. 2001).
4.7
TardiveDyskinesia
According to current concepts, tardive dyskinesia seen after long-term treat-
ment with some neuroleptics involves progressive neuronal damage resulting
from excitotoxicity and free radical production (DeKeyser 1991; Cadet and
Kahler 1994). At the level of the striatum, chronic blockade of D2 inhibitory
dopaminergic receptors localized on glutamatergic terminals from the cortex
mayleadtoapersistent,enhancedreleaseofglutamatethateventuallydamages
output neurons (DeKeyser 1991; Gunne and Andren 1993).
4.8
Glaucoma
Excitotoxicity has also been implicated in glaucoma. Mild chronic intravitreal
elevationinglutamateconcentrationbyserialintravitrealglutamateinjections
resulted in death of retinal ganglion cells. Concurrent daily injections of me-
mantine completely prevented this cell death (Vorwerk et al. 1996). As such,
the memantine follow-up compound neramexane (MRZ 2/579) could also be
useful for the treatment of glaucoma and this possibility is presently being
tested as a proof concept for the neuroprotective effects of moderate afﬁn-
ity uncompetitive NMDA receptor antagonists in chronic neurodegenerative
diseases. Retinal ischaemia induced in rats by elevating intraocular pressure
also caused an elevation in the mean vitreous concentration of glutamate and
glycine and caused pronounced loss of retinal ganglion cells (Lagreze et al.
1998).
4.9
HIVDementia
There are a number of indications that glutamate might be involved in some
aspects of acquired immunodeﬁciencysyndrome (AIDS)-related neurological
deﬁcits (Lipton 1992b). Gp120 (HIV coat protein) produces toxicity in vitro
that is attenuated by NMDA receptor antagonists such as dizocilpine (MK-
801) and memantine (Lipton 1992a). Neurodegeneration in transgenic mice
over expressing gp120 was attenuated by memantine (Toggas et al. 1996). This276 C.G. Parsons et al.
toxicity is probably secondary to glutamate release from glial cells rather than
a direct agonistic effect of Gp120.
4.10
MultipleSclerosis
In a mouse model of autoimmune encephalomyelitis (EAE) there is a deﬁcit
of astroglial enzymes (glutamate dehydrogenase and glutamine synthase) re-
sponsible for degradation of glutamate taken up from the extracellular space
(HardinPouzet et al. 1997). This may lead to an increase in extracellular glu-
tamate and neurotoxicity seen in this disease. Memantine dose-dependently
ameliorated neurological deﬁcits in rodents with EAE. This was not via inter-
actions with the immune system per se and implies that effector mechanisms
responsible for reversible neurological deﬁcits in EAE may involve NMDA re-
ceptors(Wallstrometal.1996).Oligodendrocyteexcitotoxicityviaoveractiva-
tionofAMPAandkainate receptorscouldalsobeinvolvedinthepathogenesis
ofsuchdemyelinatingdisorders(Matuteetal.2001).Braindamageinmultiple
sclerosis includes both glial activation and pathological changes in axons. The
expression patterns of both group I and II mGluRs in multiple sclerosis tissue
differed signiﬁcantly from the patterns in control tissue. Changes in mGluR
immunoreactivity were also observed in glia. A diffuse increase in the expres-
sion of mGluR5 and mGluR2/3 was detected in reactive astrocytes in multiple
sclerosis lesions (Geurts et al. 2003).
4.11
Astroglioma
Implantedastrogliomacellssecreteglutamateinvivo, andthoseshowinghigh
glutamate release have a distinct growth advantage in host brain that is not
present in vitro. Treatment with dizocilpine or memantine slowed the growth
of glutamate-secreting tumours in situ, suggesting that activation of NMDA
receptors facilitates tumour expansion (Takano et al. 2001). Glutamate antag-
onists have also been shown to inhibit proliferation of various human tumour
cells in vitro, but the concentrations required were very high and probably not
of therapeutic relevance (Rzeski et al. 2001). This suggests that astroglioma
cellssecreteglutamatetodestroyhealthysurroundingtissueandtherebymake
space for tumour expansion. These ﬁndings support a new approach for ther-
apy of brain tumours, based upon antagonizing glutamate secretion or its
target receptors.
4.12
Epilepsy
Although epilepsy was one of the ﬁrst suggested therapeutic applications of
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onlyfewsuchagentsreachedclinicaltestingforthisindicationandthesefailed
to show sufﬁcient beneﬁts and produced serious side-effects (Troupin et al.
1986; Leppik et al. 1988; Sveinbjornsdottir et al. 1993).
Preclinical data indicate that NMDA receptor antagonists will probably not
be useful as a monotherapy in epilepsy. However, the observation that NMDA
receptor antagonists greatly enhance the anticonvulsive potency of AMPA
receptorantagonists(Löscheretal.1993)andconventionalanti-epilepticdrugs
(Czuczwaretal.1996),therebyallowingsigniﬁcantdosereductions,opensnew
avenues in this regard. Drugs that interact with more than one anticonvulsant
targetmayshowsynergisticanticonvulsantactionsbutmaynothaveincreased
toxicity. Indeed, highly effective, broad-spectrum antiepileptic drugs such as
felbamate and topiramate, may act through such multiple mechanisms.
Transient stimulation of group I mGluRs induces persistent prolonged
epileptiformdischargesviaanactivationofERK1/2inthehippocampus(Zhao
et al. 2004). Group I mGluR antagonists show anticonvulsant efﬁcacy against
pentylenetetrazole-induced seizures, kindling, and kindling-related learning
deﬁcits. It was concluded that mGluR1 and mGluR5 play a speciﬁc role in
the convulsive component of kindling and that the beneﬁcial action of the
antagonists on kindling-induced impairments in shuttle-box learning may be
associated with their effect on glutamatergic synaptic activity (Nagaraja et al.
2004). Mice lacking mGluR7 exhibit an increased susceptibility to seizures,
suggesting a preponderance of excitation (Sansing et al. 2001).
4.13
ChronicPain
Despiteintensiveresearchontheneurobiologicalmechanismsofchronicpain,
this therapeutic area remains one of the least satisfactorily covered by current
drugs.Thereisconsiderablepreclinicalevidencethathyperalgesiaandallody-
nia following peripheral tissue or nerve injury is not only due to an increase
in the sensitivity of primary afferent nociceptors at the site of injury but also
depends on NMDA receptor-mediated central changes in synaptic excitability
(Zieglgänsberger and Tolle 1993; Sandkühler and Liu 1998; Eide 2000; Parsons
2001; Fundytus 2001).
The uncompetitive NMDA receptor antagonist ketamine has been available
for clinical use as an anaesthetic for 40 years (Domino et al. 1965). Ketamine
is effective in various animal models of hyperalgesia and allodynia and has
been reported to have antinociceptive effects in some of these models at doses
devoidofobviousside-effects.Others,however,havereportedthattheeffectsof
ketamineareonlyseenatdosesproducingataxia(seeParsons2001forreview).
Ketamine reportedly inhibits the area of secondary hyperalgesia induced by
chemical (Park et al. 1995) or thermal stimuli (Ilkjaer et al. 1996; Warncke
etal.1997)andinhibitstemporalsummationofrepeatedmechanical(Warncke
et al. 1997) and electrical stimuli (Arendtnielsen et al. 1995; Andersen et al.278 C.G. Parsons et al.
1996). There is evidence for tonic NMDA receptor activation in inﬂammatory
hyperalgesia(Boxalletal.1998)andinthemechanismsunderlyingthereduced
effectiveness of opioids in chronic neuropathic pain states (Mao et al. 1995;
Cai et al. 1997; Fan et al. 1998; Yashpal et al. 2001). Several controlled trials in
patients withperipheral neuropathic pain haveshown positiveeffectsof acute
injections of ketamine on spontaneous ongoing pain (Eide et al. 1994; Max
et al. 1995; Nikolasjen et al. 1996; Felsby et al. 1996) central neuropathic pain
(Eide et al. 1995b), ﬁbromyalgia (Pud et al. 1998), and chronic ischaemic pain
(Persson et al. 1998). After pre- and peri-operative treatment with low-dose
ketamine, postoperative pain relief has been evidenced by reduced morphine
consumption,buttheintensityofongoingpost-operativepainwaslessaffected
(Roytblat et al. 1993; Ngan Kee et al. 1997; Fu et al. 1997). Oral treatments
with NMDA receptor antagonists have thus far been disappointing and often
associated with side-effects (e.g. Haines and Gaines 1999). Nevertheless, there
is great potential in the combination of therapeutically safe NMDA receptor
antagonists with opioids in the treatment of chronic pain (Elliott et al. 1995;
Eide et al. 1995a; Schmid et al. 1999).
Memantine also blocks and reverses thermal hyperalgesia, mechanical al-
lodynia in rat models of painful mononeuropathy without obvious effects on
motor reﬂexes following systemic (Carlton and Hargett 1995; Eisenberg et al.
1993, 1995; Suzuki et al. 2001) and local spinal administration (Chaplan et al.
1997).Althoughthehypothesisunderlyingtheabilityofthismoderateafﬁnity
open channel blocker to differentiate between phasic physiological and tonic
excitotoxic pathological activation of NMDA receptors has gained relatively
wide acceptance (Mealing et al. 1997; Kornhuber and Weller 1997; Parsons
et al. 1999) it is still unclear how such compounds could differentiate between
normal and abnormal synaptic activation of NMDA receptors.
A n o t h e rp r o m i s i n gt a r g e tf o rN M D Ar e c e p t o ra n t a g o n i s mi st h eg l y c i n e B
modulatorysite(DanyszandParsons1998).Indeed,systemicallyactiveglycineB
antagonists have good therapeutic indices following systemic administration
in models of hyperalgesia and allodynia (see Parsons 2001 for references; plus
Quartaroli et al. 2001).
TheNR2B-selectiveagenttraxoprodilhasalsobeenreportedtobeeffective
in suppressing hyperalgesia in animal models of chronic pain (carrageenan,
capsaicin and allodynia in neuropathic rats) at doses devoid of negative side-
effects in motor co-ordination or behaviour (Taniguchi et al. 1997; Boyce
et al. 1999). A good separation was also reported for (+/−)-Ro 25–6981 (Boyce
et al. 1999), indicating that NR2B-selective antagonists may also have clinical
utility for the treatment of neuropathic and other pain conditions in man with
a reduced side-effect proﬁle (Chizh et al. 2001).
RecentdataalsoindicatethatperipheralNMDAreceptorsareinvolvedinin-
ﬂammatorysomaticandvisceralpain(Leemetal.2001).Peripheralglutamate
receptorsareassociatedwithunmyelinatedaxons(Carltonetal.1995),andthe
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increases during peripheral sensitization due to inﬂammation (Carlton and
Coggeshall1999;CoggeshallandCarlton1999).Immunohistochemicalstudies
indicate that NR1 subunits are expressed on the cell bodies and peripheral
terminals of primary afferent nerves innervating the colon and may provide
a novel mechanism for development of peripheral sensitization and visceral
hyperalgesia (McRoberts et al. 2001).
Evidence from experimental pain research has revealed that mGluRs play
a pivotal role in nociceptive processing, inﬂammatory pain and hyperalgesia.
mGluRs have been implicated in dorsal horn neuronal nociceptive responses
and pain associated with short-term inﬂammation (Neugebauer 2002) as well
as its emotional component involving limbic structures such as the amygdala
(Han et al. 2004).
Peripheral group II mGluRs reduce inﬂammation-induced mechanical al-
lodynia and may mediate endogenous anti-allodynia effects, which speed re-
covery from inﬂammation-induced hypersensitivity (Yang and Gereau 2003).
mGluR subtypes are differentially expressed in spinal cord dorsal horn in re-
sponse to persistent inﬂammation (Dolan et al. 2003). Recent ﬁndings suggest
that the induction of LTP in the spinal dorsal horn by high-frequency, high-
intensity stimulation of afferent C ﬁbres requires the activation of mGluR1/5
(Azeku et al. 2003). Antisense oligonucleotide knockdown of spinal mGluR(1)
attenuatesthermalhyperalgesiaandmechanicalallodyniainratsinjectedwith
CFAinonehindpaw,suggestingaroleformGluR(1)inpersistentinﬂammatory
nociception (Fundytus et al. 2002). Group I mGluR antagonism, and Group II
orIIImGluRagonism,caneffectivelydecreasethedevelopmentofmechanical
and cold hypersensitivity associated with chronic constriction injury (CCI) in
rats. The results can be interpreted to suggest that activation of spinal group I
mGluRs contributes to spinal plasticity leading to the development of neu-
ropathic pain, and that this effect is offset by activation of groups II and III
mGluRs (Fisher et al. 2002).
4.14
Addiction
It is believed that phenomena such as sensitization, tolerance and drug-
dependence might also involve synaptic plasticity. In fact, numerous studies
indicate that NMDA receptor antagonists block sensitization to amphetamine
and cocaine as well as tolerance and dependence to ethanol and opioids in an-
imalmodels(TrujilloandAkil1991;PasternakandInturrisi1995;Trujilloand
Akil 1995; Mao 1999). Recent studies indicate that the uncompetitive NMDA
receptorantagonistsdextromethorphan,memantineandneramexanenotonly
prevent the development of morphine tolerance, but also reverse established
tolerance in the continuing presence of this opioid, prevent the expression of
withdrawal symptoms in rats (Popik and Skolnick 1996; Popik and Danysz
1997; Popik and Kozela 1999; Houghton et al. 2001) and attenuate the expres-280 C.G. Parsons et al.
sion of opioid physical dependence in morphine-dependent humans elicited
byadministrationofnaloxone(Bisagaetal.2001).Likewise,systemicallyactive
glycineB antagonists attenuate both physical dependence to morphine and the
development of tolerance to the antinociceptive effects of opioids following
repeated administration (Pasternak and Inturrisi 1995; Popik et al. 1998; Be-
lozertseva et al. 2000a; Belozertseva et al. 2000b; for review see Danysz and
Parsons 1998).
Under certain conditions NMDA receptor antagonists (e.g. dizocilpine) in-
hibitsensitization(locomotorresponse)torepetitiveadministrationofcocaine
(Carey et al. 1995; see Karler and Calder 1992; Sripada et al. 2001). The sensi-
tization to cocaine in rats seems to be related to an increase in AMPA receptor
sensitivity in the nucleus accumbens and an increased glutamate release in
response to cocaine challenge (Pierce et al. 1996). NMDA receptor antago-
nists block the acquisition of cocaine-induced place preference, but not its
expression(CervoandSamanin1995).Also,establishedself-administrationof
cocaine, and its development in rats is decreased by dextromethorphan (Pul-
virenti et al. 1992; Ranaldi et al. 1997), probably through blockade of NMDA
receptors in the nucleus accumbens (Pulvirenti et al. 1992). A recent study
identiﬁed group II mGluRs as a pharmacotherapeutic target for craving and
relapse prevention associatedwith cocainecueexposure (Baptistaetal. 2004).
In the nucleus accumbens, a key structure for the effects of all addictive
drugs, presynaptic cannabinoid CB1 receptors and postsynaptic mGluRs play
a pivotal role in LTD (Marsicano et al. 2002; Azad et al. 2004). Also, in the CA1
region of the hippocampus activation of postsynaptic group I metabotropic
glutamate receptors evoked LTD and the release of endocannabinoids from
pyramidal cells. Since the effect of the mGluR agonist was still present in the
CB1 knockout mouse, it is suggested that endocannabinoids, acting on a non-
CB1 cannabinoidreceptor,contributetothedepressionofmGluRinducedLTD
(Rouach and Nicoll 2003).
Asingleinvivococaineadministrationabolishesendocannabinoid-depen-
dent LTD. This effect of cocaine was not present in mice lacking D1 dopamine
r e c e p t o r sa n dw a sb l o c k e db yas e l e c t i v eD 1 receptor and NMDA receptor
antagonist,suggestingtheinvolvementofD1 andNMDAreceptors(Fourgeaud
et al. 2004).
Ethanol is an NMDA receptor antagonists (e.g. Mirshahi and Woodward
1995) and the afﬁnity is within the range seen in the brains of alcohol abusers.
It has been suggested that the effects of ethanol may be related to selective
actions at NR2B receptors (Yang et al. 1996; Lovinger and Zieglgansberger
1996; Follesa and Ticku 1996; Smothers et al. 2001).
Apost-mortemstudyonthebrainsofalcoholicsshowedamodestincreased
binding for [3H]glutamate and [3H]CGP-39653—a competitive NMDA recep-
tor antagonist (Freund and Anderson 1996). In humans with a history of alco-
hol abuse, an increase in immunoreactivity toward AMPA GluR2 and GluR3
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corticotropin-releasinghormone(CRH)1receptors,thedelayedandenhanced
stress-induced alcohol drinking was associated with an upregulation of NR2B
subunits (Sillaber et al. 2002).
Blockade of NMDA receptors inhibits some aspects of alcohol dependence.
Memantine given before ethanol administration prevented the development
ofethanoldependenceinducedbyintragastricadministrationofethanol,sup-
porting the notion that NMDA receptors are involved in the development of
ethanol dependence (Kotlinska 2001). In an alcohol ‘craving’ model, meman-
tineandneramexaneinfuseds.c.failedtochangealcoholintakeundernormal
conditions, but completely inhibited alcohol consumption during the relapse
phase(Holteretal.1996;Holteretal.2000).Thereareseveralpossibilitieshow
NMDAreceptorantagonistsexertthiseffect:(1)producealcohol-likeeffects—
memantine shows partial generalization to the ethanol cue in rats trained to
discriminate ethanol (Bienkowski et al. 1997; Hundt et al. 1998); (2) block
recognition of the alcohol cue; (3) inhibit association of environmental cues
with alcohol use; or, (4) block the reinforcing action of ethanol. Neramexane
is currently in phase II clinical trials for alcohol dependence.
Acamprosate has been approved as an anti-craving drug in most European
countriesforseveralyearsandmostrecentlyalsointheUSA.Acamprosateand
theopioidreceptorantagonistnaltrexonerepresenttheﬁrstagentstoshowpos-
itiveresultsinproperlyconductedclinicaltrials(LittletonandZieglgänsberger
2003).Thepharmacologyofacamprosateisstillpoorlyunderstood.Ithasbeen
reported that acamprosate modulates NMDA receptor function after binding
to a spermidine-sensitive site (Naassila et al. 1998). Unexpectedly, in a recent
patch clamp study, acamprosate reversed polyamine potentiation on NMDA-
or glutamate-induced currents only in a subset of cultured neurons (Popp and
Lovinger 2000). Studies performed in cultured hippocampal neurons and in
Xenopus oocytes or HEK-293 cells expressing NR1a/2A and NR1a/2B receptor
assemblies were also unable to show any interaction of acamprosate with the
polyamine site or inﬂuence on agonist afﬁnity (Rammes et al. 2001). However,
in this same study, acamprosate produced similar increases in NR1 and NR2B
receptor expression in vivo to those seen following acute treatment with di-
zocilpine or memantine, indicating that acamprosate may produce changes in
the CNS that are similar to those seen following NMDA receptor antagonists,
and these changed may, in turn, underlie the effects of both kinds of drugs in
the treatment of alcohol abuse.
4.15
Anxiety
Various compounds that decrease glutamatergic transmission via blockade of
NMDA or group I mGlu receptors produce anxiolytic- and antidepressant-
like actions in animal tests and models. Anxiolytic activity resulting from
NMDAreceptorantagonismwasreportedasearlyas1986(BennettandAmrick282 C.G. Parsons et al.
1986; Stephens et al. 1986). Later, anxiolytic activity of uncompetitive and
competitive NMDA receptor antagonists have been shown in the conﬂict test,
social interaction test, elevated plus maze, separation-induced vocalization in
rat pups and by blockade of fear potentiated startle (see Danysz and parsons
1998).Similarly,partialagonistsoftheglycineB sitehavebeenshowntoposses
anxiolytic potential. However, this effect is not seen in all animal models and
is not related to intrinsic activity of these agents (Karcz-Kubicha et al. 1997).
Moreover, full antagonists of the glycineB siteshowinggoodpenetrationtothe
brain (Licostinel; MRZ 2/576, L-701,324) failed to show a consistent anxiolytic
proﬁle (Wiley et al. 1995; Karcz-Kubicha et al. 1997). Moreover, there is no
good reason to believe that NMDA receptor antagonists will be better than
classical anxiolytic agents such as benzodiazepines.
More promising preclinical data have been generated with the competi-
tive metabotropic mGluR2 agonist LY-354740 (Chojnacka-Wojcik et al. 2001).
This compound seems to cause only mild sedation in mice, does not disturb
motor coordination and has no potential to cause dependence. Therefore,
similar ligands or positive modulators of mGluR2 receptors may become the
anxiolytics of the future, free from the side-effects characteristic of benzo-
diazepine. However, this enthusiasm might be dampened by problems with
ADME(absorption,distribution,metabolism,excretion).Recently,structure–
activity relationship studies led to the discovery of a new, orally active mGlu5
receptor antagonist with anxiolytic activity (Roppe et al. 2004). In addition,
highly potent orally active group II and group III mGluR agonists have proved
toeffectiveinanimalmodelsforanxietyandpsychosis(Paluchaetal.2004;Col-
lado et al. 2004). Metabotropic glutamate receptors (mGluRs) have also been
implicated in regulating anxiety, stress responses and the neurobehavioural
effects of psychostimulants, suggesting group II mGluRs as a pharmacother-
apeutic target for craving and relapse prevention associated with cocaine cue
exposure (Baptista et al. 2004).
4.16
Schizophrenia
Several lines of evidence have implicated NMDA receptor hypofunction in the
pathophysiology of schizophrenia. The administration of certain, but not all,
uncompetitive NMDA receptor antagonists exacerbates psychotic symptoms
in schizophrenics and mimics schizophrenia in non-psychotic subjects (Coyle
et al. 2003; Konradi and Heckers 2003).
Recent studies have identiﬁed abnormalities associated with schizophrenia
that interfere with the activation of the glycine modulatory site of the NMDA
receptor (Coyle and Tsai 2004).Further, the useof NMDA receptor glycinesite
agonistssuchasglycine,d-serineord-cycloserineinclinicaltrialshasdemon-
strated some efﬁcacy in ameliorating the negative symptoms and cognitive
disabilities in schizophrenics (Coyle and Tsai 2004).Excitatory Amino Acid Neurotransmission 283
The mGluRs are highly enriched in PFC—a brain region critically involved
in the regulation of cognition and emotion. A disturbance of glutamater-
g i ct r a n s m i s s i o nh a sb e e ns u g g e s t e dt oc o n t r i b u t et ot h ed e v e l o p m e n to f
schizophrenicpathophysiologybasedprimarilyontheabilityofionotropicglu-
tamatereceptorantagoniststoinduceschizophrenic-likesymptoms.Emerging
evidencesuggeststhatmGluRsareviabledrugtargetsforneuropsychiatricdis-
ordersassociatedwithreducedglutamatergicfunctioninthePFC(Mareketal.
2000). Group II mGluR agonists have been reported to reduce the behavioural
and neurochemical effects of phencyclidine (PCP) administration (Olszewski
et al. 2004). PCP administration elicits positive and negative symptoms that
resemble those of schizophrenia and is widely accepted as a model for the
study of this human disorder.
4.17
Depression
In humans, the antidepressant activity of NMDA receptor antagonists has not
been evaluated extensively (Skolnick 1999). In animal models of depression,
NMDA receptor antagonists have been reported to exert positive effects in
most studies (Trullas 1997). This concerns mainly the forced swim test (Maj
1992; Moryl et al. 1993; Przegalinski et al. 1997) and stress-induced anhe-
donia (Papp and Moryl 1994). Amantadine but not memantine was effective
againstreserpine-inducedhypothermia(Moryletal.1993).Intheforcedswim
test, both amino-adamantanes produced speciﬁc antidepressive-like activity
(Moryl et al. 1993).
Possible synergistic interactions between classical antidepressants and un-
competitive NMDA receptor antagonists in the forced swim test were recently
investigated. Fluoxetine, which was inactive when given alone, showed a posi-
tive effect when combined with amantadine, memantine or neramexane, sug-
gesting that the combination of traditional antidepressant drugs and NMDA
receptorantagonistsmayproduceenhancedantidepressiveeffects(Rogozetal.
2002). This was proposed to be of particular relevance for antidepressant-
resistant patients. In clinical trials the glutamate release inhibitor lamotrigine
has also been shown to have antidepressant activity (Nikolasjen et al. 1996;
Sporn and Sachs 1997; Eide 2000). In summary, clinical evidence supporting
the antidepressant efﬁcacy of NMDA antagonists is scarce. However, if effec-
tive, NMDA antagonists may show unique rapidity of clinical efﬁcacy. Thus,
furtherevaluationofthisdrugclassinthetreatmentofdepressionwouldseem
to be reasonable.
Compounds that decrease glutamatergic transmission via blockade of
group I mGluRs produce anxiolytic- and antidepressant-like action in animal
testsandmodels.Inrecentstudies,groupIIandIIImGluR-agoniststhatreduce
glutamatereleasehavebeensuggestedtoplayaroleinthetherapyofbothanx-
ietyanddepression(Paluchaetal.2004;Chakietal.2004).CB1 receptoractiva-284 C.G. Parsons et al.
tion reduces boththe releaseand uptake of glutamate in vitro; and bothmech-
anismsaredependentonmGluRactivation(Brownetal.2003b).Therelevance
oftheseﬁndingsfortheanxiolyticpropertiesofcannabisremainstobeshown.
5
Summary
At present there seems to be a consensus that competitive AMPA and NMDA
receptorantagonists a low chance of ﬁnding therapeutic applications.Antago-
nists showing moderate afﬁnity and satisfactory selectivity for certain NMDA
receptor subtypes seem to have a more favourable proﬁle. From the therapeu-
tic point of view, the real challenge is not only to improve the symptoms of
diseases, but also to interfere with their pathomechanism, i.e. prevent pro-
gression. The most promising symptomatic indications for NMDA receptor
antagonists seemtobevariousforms ofdementia,alcoholabuse,andpossibly
some forms of chronic pain such as phantom pain and postoperative pain, in
particularly in combination with opioids. Clinical evidence for neuroprotec-
tive activity of glutamate antagonists in chronic neurodegenerative diseases
is scarce. Results with NMDA receptor antagonists in clinical trials of stroke
and trauma have been very disappointing. Some degree of hope remains for
NR2B-selective NMDA receptor antagonists, AMPA and/or kainate receptor
antagonists and combinations thereof with, for example, additional blockade
of voltage-activated channels.
In terms of clinical proof of neuroprotective effects in chronic neurodegen-
erative diseases, so far there are promising clinical results in ALS only with
riluzole,andeventhen,theincreaseofsurvivalobtainedwasonlymodest.The
failureofremacemideinarecentstudyinHuntington’sdiseasewasclearlyabig
setback. On the other hand, the moderate-afﬁnity NMDA receptor antagonist
memantineprovidesclearsymptomaticimprovementindementiainbothclin-
icalandpreclinicalsituations,andthepreclinicaldatapredictneuroprotective
effects, substantiated by numerous animal models.
AMPA receptor antagonists acting at the 2,3-benzodiazepine modulatory
site seemtohave abettersafetyproﬁlethancompetitiveagents suchasNBQX,
pr obablyd uetotheirbettersol ubilityandassocia tedred ucedside-effectssuch
as renal toxicity. It is still not clear for which indications they might be useful,
althoughtheireffectsinanimalmodelsofacuteandchronicneurodegenerative
diseases look quite promising.
Someofthemodulatorsofglutamatefunctionindeedstillhaveapromising
future as therapeutics for numerous CNS diseases. The importance of gluta-
mate receptors in both physiological and pathological processes emphasizes
the need to develop agents that selectively modulate the latter (Parsons et al.
1999; Hardingham and Bading 2003).Excitatory Amino Acid Neurotransmission 285
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